Form 8-K Cyclo Therapeutics, Inc. For: Aug 21
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cyclo Therapeutics (CYTH) PT Lowered to $0.95 at Ascendiant Capital
August 26, 2024 5:03 AM EDTAscendiant Capital analyst Lucas Ward lowered the price target on Cyclo Therapeutics (NASDAQ: CYTH) to $0.95 (from $2.60) while maintaining a Buy rating.
The analyst comments "Company completes enrollment in phase 3 trial, affirms regulatory timeline: On May 30, the company announced it has completed enrollment for its... More
